141 related articles for article (PubMed ID: 24400239)
1. Involvement of magnitude of ambient temperature change in nonspecific effect in perceived placebo effect on lower urinary tract symptoms: study on switching of naftopidil in patients with benign prostatic hyperplasia.
Morita T; Kubo KK; Fujisaki A; Natsui S; Nukui A; Kobayashi M; Kurokawa S
Res Rep Urol; 2013; 5():83-90. PubMed ID: 24400239
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
3. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Garimella PS; Fink HA; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia.
Griwan MS; Karthikeyan YR; Kumar M; Singh BJ; Singh SK
Urol Ann; 2014 Jul; 6(3):181-6. PubMed ID: 25125888
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Naftopidil 75 mg with Tamsulosin Hydrochloride 0.2 mg in the Treatment of Lower Urinary Tract Symptoms with Benign Prostatic Hyperplasia.
Shigemura K; Yamamichi F; Matsumoto M; Tanaka K; Yamashita M; Arakawa S; Fujisawa M
Low Urin Tract Symptoms; 2012 Sep; 4(3):136-9. PubMed ID: 26676620
[TBL] [Abstract][Full Text] [Related]
6. Early Efficacy of an α1 Adrenoceptor Antagonist, Naftopidil, against Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.
Ishizuka O; Nishizawa O; Takeda M; Nomura T; Kagawa S
Low Urin Tract Symptoms; 2011 Sep; 3(2):79-85. PubMed ID: 26676391
[TBL] [Abstract][Full Text] [Related]
7. Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
Kadekawa K; Sugaya K; Mukoyama H; Sakumoto M; Shimabukuro H; Shimabukuro S; Matayoshi Y; Onaga T; Ashitomi K; Nishijima S
Low Urin Tract Symptoms; 2016 May; 8(2):100-5. PubMed ID: 27111621
[TBL] [Abstract][Full Text] [Related]
8. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
9. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
10. The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study.
Xue Z; Lin Y; Jiang Y; Wei N; Bi J
BMC Urol; 2018 Dec; 18(1):115. PubMed ID: 30545338
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
12. The role of naftopidil in the management of benign prostatic hyperplasia.
Hara N; Mizusawa T; Obara K; Takahashi K
Ther Adv Urol; 2013 Apr; 5(2):111-9. PubMed ID: 23554846
[TBL] [Abstract][Full Text] [Related]
13. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
[TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy of α1-Adrenargic Receptor Antagonist Naftopidil 75 mg/day in Patients with Benign Prostatic Hyperplasia.
Kadekawa K; Sugaya K; Ashitomi K; Nishijima S
Low Urin Tract Symptoms; 2010 Sep; 2(2):106-12. PubMed ID: 26676292
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
16. Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Masumori N; Hashimoto J; Itoh N; Tsukamoto T;
Scand J Urol Nephrol; 2007; 41(5):422-9. PubMed ID: 17853040
[TBL] [Abstract][Full Text] [Related]
17. Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?
Zhang LT; Park JK
World J Nephrol; 2015 Feb; 4(1):138-47. PubMed ID: 25664256
[TBL] [Abstract][Full Text] [Related]
18. Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
Yoshida M; Sugiyama Y; Masunaga K; Maeda Y; Satoji Y; Nagata T; Inadome A
Drugs Today (Barc); 2007 Jun; 43 Suppl B():1-7. PubMed ID: 17612712
[TBL] [Abstract][Full Text] [Related]
19. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
Komiya A; Suzuki H; Awa Y; Egoshi K; Onishi T; Nakatsu H; Ohki T; Mikami K; Sato N; Araki K; Ota S; Naya Y; Ichikawa T
Int J Urol; 2010 Jun; 17(6):555-62. PubMed ID: 20370847
[TBL] [Abstract][Full Text] [Related]
20. Association Between Ambient Temperature and Lower Urinary Tract Symptoms: A Hospital-Based Cross-Sectional Analysis.
Shim SR; Kim JH; Doo SW; Yang WJ; Song ES; Song YS
Low Urin Tract Symptoms; 2018 Jan; 10(1):38-44. PubMed ID: 27438480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
